0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Confounders Regarding the Association of Insulin Resistance and Alzheimer Disease

Sevilay Muratli, MD1; Ozlem Soyluk, MD2; Fatih Tufan, MD2
[+] Author Affiliations
1Department of Internal Medicine, Division of Geriatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
2Department of Gerontology, Faculty of Medical Sciences, Istanbul University, Istanbul, Turkey
JAMA Neurol. 2016;73(2):239-240. doi:10.1001/jamaneurol.2015.3983.
Text Size: A A A
Published online

Extract

To the Editor We read the article by Willette et al1 with interest. The findings of this study are important because insulin resistance is a growing health problem, and measures to decrease the incidence of Alzheimer disease (AD) are urgently needed. However, we have some comments on this well-designed and well-performed study.

First, checking fasting glucose levels only once may be insufficient to diagnose or exclude diabetes mellitus (DM). For an accurate diagnosis of DM, fasting glucose levels of 126 mg/dL or greater on 2 occasions (to convert to millimoles per liter, multiply by 0.0555), a glycated hemoglobin level of 6.5% or greater (to convert to proportion of total hemoglobin, multiply by 0.01), a random blood glucose level of 200 mg/dL or greater with accompanying symptoms, or a second-hour blood glucose level at 75-g oral glucose tolerance test of 200 mg/dL or greater are needed. Older adults with DM, especially, may have normal fasting blood glucose levels.2 To draw more accurate conclusions regarding the association of insulin resistance and AD, measuring postprandial glucose levels and/or glycated hemoglobin levels would prove beneficial.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

September 1, 2015
Auriel A. Willette, PhD; Barbara B. Bendlin, PhD; Erika J. Starks, BS; Alex C. Birdsill, PhD; Sterling C. Johnson, PhD; Bradley T. Christian, PhD; Ozioma C. Okonkwo, PhD; Asenath La Rue, PhD; Bruce P. Hermann, PhD; Rebecca L. Koscik, PhD; Erin M. Jonaitis, PhD; Mark A. Sager, MD; Sanjay Asthana, MD
1Department of Food Science and Human Nutrition, Iowa State University, Ames2Neuroscience Interdepartmental Program, Iowa State University, Ames
3Clinical Science Center, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison
3Clinical Science Center, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison
3Clinical Science Center, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison5Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin
6Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison
4Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison
3Clinical Science Center, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison5Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin
JAMA Neurol. 2015;72(9):1013-1020. doi:10.1001/jamaneurol.2015.0613.
February 1, 2016
Auriel A. Willette, PhD; Barbara B. Bendlin, PhD
1Iowa State University, Ames
2University of Wisconsin–Madison
JAMA Neurol. 2016;73(2):240-241. doi:10.1001/jamaneurol.2015.3986.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

327 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();